Falls and Dysphagia (new publication co-authored by BSN)

This post will be of interest to those dealing with falls and/or dysphagia (swallowing difficulty).

Local support group member Phil Myers and I co-authored a case study on falls and dysphagia in the latest issue of the Association of Frontotemporal Degeneration (AFTD) newsletter.  The case study is about “Jackie Riddle” — a composite of my father’s PSP symptoms (confirmed through brain donation) and Phil’s wife Jackie’s PSP symptoms (also autopsy-confirmed).  Though “Jackie Riddle” had PSP, since the focus of the case study is on falls and dysphagia, all of our BSN group members, regardless of diagnosis, will find something of value here.

The newsletter is written for healthcare professionals but I’m fairly certain the language is understandable.  We assumed that healthcare professionals are completely un-knowledgeable about PSP, fall prevention, and treatment of dysphagia.

There are also sections in the newsletter specifically for healthcare professionals working at care facilities.  So if any of you has a loved one in a care facility, those sections may be particularly helpful for staff.

The last two pages of the newsletter are my ideas for practical things that can be done about falls and dysphagia.  Again, though it’s titled “in PSP,” these ideas apply to all four disorders in our BSN group.

Check it out; it’s hot off the presses:

www.theaftd.org/wp-content/uploads/2015/07/PinFTDcare_Newsletter_summer_2015.pdf

Robin

Therapeutic advances and research update in MSA and PSP

This post may be of interest to those wanting to know about what key research in PSP and MSA has taken place in the last few years, and what research is ongoing or recruiting.

This review article on PSP and MSA clinical trials was just published last week.  The article is written for MSA and PSP researchers, explaining how trials since 2013 have been conducted and highlighting priority areas for future therapeutic research.  The lead author is Werner Poewe, MD, an Austrian physician and researcher.  I believe at the most recent Movement Disorder Society meeting in San Diego, he led a discussion with MSA researchers.  Perhaps he reviewed his article at the meeting.

The article notes that an earlier study of riluzole in MSA and PSP proved the feasibility of conducting large controlled trials in these two disorders.  And the study validated disease-specific rating scales for MSA and PSP.  Nearly 800 subjects were enrolled in that study.  The results, published in 2009, were negative for the medication itself.

But that large riluzole study kicked off other trials — two large clinical trials in MSA (rasagiline, rifampicin) and two large clinical trials in PSP (tideglusib, davunetide).  Those four trials failed as well.  The authors describes those trials in detail.

The article lists all of the other trials conducted since 2013 in PSP and MSA, whether results were published or not.  These include a lithium trial in MSA, two droxidopa trials in MSA, a fluoxetine trial in MSA (unpublished), a high-dose CoQ10 trial (2400mg/day) in PSP, and a valproic acid trial in PSP (unpublished).  Unfortunately one rasagiline study in PSP failed to enroll the necessary number of participants.

Though the therapeutic agents being tested in these trials failed, the studies themselves “have made important contributions to our ability to refine designs in future clinical studies targeting these conditions. As a whole they have shown that enrolling sufficient numbers of patients into trials of the less common forms of degenerative parkinsonism is feasible and that this can be accomplished within reasonable time frames.”

The authors note that despite recent trials in PSP and MSA, “there is still a profound lack of symptomatic trials for these disorders.”

The authors state:  “Although autonomic dysfunction is a key driver of disability in MSA, new drugs to treat OH, such as droxidopa, have not been tested in trials specifically enrolling MSA cases only. Likewise, none of the non-pharmacological measures such as exercise-based approaches that are a central part of palliative therapy for patients with MSA or PSP have been tested in properly designed clinical trials.”

The authors call for future research to address two main areas of need:  “improving symptomatic control, independence and well-being of patients by symptomatic interventions, and altering the course of disease by interfering with the mechanisms underlying progressive neurological impairment and disability.”

In case you are interested in exploring the ongoing trials or trials not yet recruiting in MSA and PSP, see the following list:  (If a trial is recruiting, I’ve listed the NIH clinical trial number so that you can look up info on clinicaltrials.gov)

MSA

  • two for droxidopa (one recruiting, NCT02071459, and one isn’t)
  • autologous mesenchymal stem cells (not recruiting)
  • EGCG – a green tea extract (recruiting, NCT02008721)
  • water/peudoephedrine (recruiting, NCT02149901)
  • AFFITOPE – active immunization against alpha-synuclein (recruiting, NCT02270489),
    nebivolol (not recruiting)
  • AZD3241 (the paper says not recruiting but it’s now recruiting, NCT02388295)

PSP

  • bone marrow stem cell therapy (ongoing, NCT01824121)
  • TPI-287 (ongoing, NCT02133846)

I think most of you will want to stop reading here.  Below, I’ve provided the abstract.

Robin


Abstract

Movement Disorders. 2015 Jul 30.
Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.
Poewe W, Mahlknecht P, Krismer F.

Abstract
Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are relentlessly progressive neurodegenerative diseases leading to severe disability and ultimately death within less than 10 y. Despite increasing efforts in basic and clinical research, effective therapies for these atypical parkinsonian disorders are lacking. Although earlier small clinical studies in MSA and PSP mainly focused on symptomatic treatment, advances in the understanding of the molecular underpinnings of these diseases and in the search for biomarkers have paved the way for the first large and well-designed clinical trials aiming at disease modification. Targets of intervention in these trials have included α-synuclein inclusion pathology in the case of MSA and tau-related mechanisms in PSP. Since 2013, four large randomized, placebo-controlled, double-blind disease-modification trials have been completed and published, using rasagiline (MSA), rifampicin (MSA), tideglusib (PSP), or davunetide (PSP). All of these failed to demonstrate signal efficacy with regard to the primary outcome measures. In addition, two randomized, placebo-controlled, double-blind trials have studied the efficacy of droxidopa in the symptomatic treatment of neurogenic orthostatic hypotension, including patients with MSA, with positive results in one trial. This review summarizes the design and the outcomes of these and other smaller trials published since 2013 and attempts to highlight priority areas of future therapeutic research in MSA and PSP.

© 2015 International Parkinson and Movement Disorder Society.

PMID:  26227071

 

“Could a vitamin or mineral deficiency be behind your fatigue?” (short article, Harvard)

Fatigue can be a symptom in all of the disorders in our local support group.  Today’s Healthbeat email from the Harvard Medical School points to one mineral and two vitamin deficiencies that may cause fatigue.  It might be worth having an MD check one’s vitamin levels to rule these out as problems if fatigue is present.

Robin

—————————————————————

Excerpts from

Could a vitamin or mineral deficiency be behind your fatigue?

Healthbeat
Harvard Medical School
August 1, 2015

The world moves at a hectic pace these days. If you feel like you’re constantly running on empty, you’re not alone. Many people say that they just don’t have the energy they need to accomplish all they need to. Sometimes the cause of fatigue is obvious — for example, getting over the flu or falling short on sleep. Sometimes a vitamin deficiency is part of the problem. It might be worth asking your doctor to check a few vitamin levels, such as the three we’ve listed below.

* Iron. Anemia occurs when there aren’t enough red blood cells to meet the body’s need for oxygen, or when these cells don’t carry enough of an important protein called hemoglobin. Fatigue is usually the first sign of anemia. A blood test to measure the number of red blood cells and amount of hemoglobin can tell if you have anemia. The first step in shoring up your body’s iron supply is with iron-rich foods (such as red meat, eggs, rice, and beans) or, with your doctor’s okay, over-the-counter supplements.

* Vitamin B12. Your body needs sufficient vitamin B12 in order to produce healthy red blood cells.  So a deficiency in this vitamin can also cause anemia. The main sources of B12 are meat and dairy products, so many people get enough through diet alone. However, it becomes harder for the body to absorb B12 as you get older, and some illnesses (for example, inflammatory bowel disease) can also impair absorption. Many vegetarians and vegans become deficient in B12 because they don’t eat meat or dairy. When B12 deficiency is diet-related, oral supplements and dietary changes to increase B12 intake usually do the trick. Other causes of B12 deficiency are usually treated with regular injections of vitamin B12.

* Vitamin D. A deficit of this vitamin can sap bone and muscle strength. This vitamin is unique in that your body can produce it when your skin is exposed to sunlight, but there also aren’t many natural food sources of it. You can find it in some types of fish (such as tuna and salmon) and in fortified products such as milk, orange juice, and breakfast cereals. Supplements are another way to ensure you’re getting enough vitamin D (note that the D3 form is easier to absorb than other forms of vitamin D).

“When DLB, PD, and PSP masquerade as MSA” (Mayo autopsy study)

We’ve been waiting for this sort of article to be published for a long time.  And we need similar articles for all the disorders in our group, not just MSA.  The article calls into question diagnostic criteria (for PD and PSP) and calls into question assumptions made by clinicians (for MSA and PD).

A fascinating article was published in the journal Neurology this week.  It’s from Mayo researchers and focuses on 134 patients who had clinical diagnoses of MSA and donated their brains between 1998 and 2014.  As you may know, Brain Support Network helps people nationally donate a loved one’s brain. We were responsible for about 25% of those 134 (clinical) MSA brain donations!

Of the 134, 125 had adequate medical records to review.  (It’s so important to provide complete medical records when you are donating a loved one’s brain!  Sadly, not everyone does.)  Of the 134 patients, only 62% actually had MSA upon brain autopsy!  The most common misdiagnosis was DLB (37% – wow!), followed by PSP (29%) and Parkinson’s Disease (15%).  (18% had other diagnoses including CBD and vascular parkinsonism.)

Those who actually had DLB and PD, not MSA, had autonomic failure — which is what led the clinicians astray in their diagnosis.  (According to the PD diagnostic criteria, severe dysautonomia in early stages is an exclusionary criteria.)

Those who actually had PSP, not MSA, had cerebellar ataxia — which is what led the clinicians astray in their diagnosis.  (According to the PSP diagnostic criteria, cerebellar ataxia is an exclusionary criteria.)  Apparently, there is an atypical form of PSP called PSP-cerebellar.  The authors note that a recent study “has shown that older onset, early falls, and vertical gaze palsy without dysautonomia may differentiate PSP-C from MSA-C.”

We have certainly seen this in our local support group — people diagnosed with MSA but it turns out they have DLB, PD, or PSP.  Happens all the time.  In our local sample, the diagnostic accuracy is closer to 50%.  Clinicians do not seem to understand that:

(a) autonomic failure can occur in DLB,

(b) hallucinations and dementia do not occur in MSA, and

(c) poor tolerance of levodopa is not the same thing as poor response to levodopa.

The diagnostic accuracy was not different between general neurologists and movement disorder specialists.

Retrospectively, the 125 patients with clinical records were diagnosed with probable MSA, possible MSA, or unknown.  49 patients met the criteria for probable MSA, 35 for possible MSA, and the remaining 41 were not assigned due to lack of clinical information (such as whether the patient was responsive to levodopa).  Of those with probable MSA or possible MSA, the diagnostic accuracy was 71% and only 60% respectively.

The authors note that “Correctly diagnosed patients with MSA had a younger age at onset and age at death than patients with PD or PSP.”  Duration of symptoms wasn’t different.

The authors looked at frequency of clinical features among the various confirmed diagnoses.

“Comparing MSA and DLB, urinary incontinence, limb ataxia, nystagmus, and pyramidal signs were more frequent in MSA. Cognitive impairment and visual hallucinations were more frequent in DLB. Comparing MSA and PD, urinary incontinence was less frequent and visual hallucinations were more frequent in PD. Comparing MSA and PSP, urinary incontinence, constipation, orthostatic hypotension, and RBD were more frequent in MSA. Vertical gaze palsy was more frequent in PSP. Frequency of levodopa responsiveness and average Mini-Mental State Examination score were not different among the groups.”

This aspect of “levodopa responsiveness” is interesting to me because we are always told that one symptom of MSA, PSP, DLB, and CBD is that there’s either no or a poor response to levodopa, as compared to PD.  I asked Dr. Neng Huang, BSN’s medical advisor, about this recently as we have a local group member whose husband was diagnosed with MSA during life but PD on brain autopsy.  Dr. Huang pointed out that “poor tolerance” of levodopa is not the same thing as “poor response.”  Many people have side effects when taking levodopa and want to discontinue it.  This seems to be viewed in the movement disorder specialist’s mind as being non-responsive rather than poor-tolerance.

The abstract makes an interesting statement about DLB.  Apparently not everyone with DLB confirmed through autopsy had dementia during life!  If someone doesn’t have dementia, they don’t qualify for a DLB diagnosis during life.  The authors wonder if the cognitive impairment was overlooked because few of the DLB-masquerading-as-MSA patients had neuropsychological evaluations.

The researchers point out that a 62% diagnostic accuracy isn’t adequate for either patient care or MSA research.  Obviously, we won’t have success with MSA research if only 62% of the participants actually have MSA!

Those are the highlights.  The abstract is copied below.  You can now find the full paper for free online:

www.ncbi.nlm.nih.gov/pmc/articles/PMC4534078/

Robin

=================================

Here’s the abstract:

Neurology. 2015 Jul 2.  [Epub ahead of print]

When DLB, PD, and PSP masquerade as MSA: An autopsy study of 134 patients.

Koga S, Aoki N, Uitti RJ, van Gerpen JA, Cheshire WP, Josephs KA, Wszolek ZK, Langston JW, Dickson DW.

OBJECTIVE:
To determine ways to improve diagnostic accuracy of multiple system atrophy (MSA), we assessed the diagnostic process in patients who came to autopsy with antemortem diagnosis of MSA by comparing clinical and pathologic features between those who proved to have MSA and those who did not. We focus on likely explanations for misdiagnosis.

METHODS:
This is a retrospective review of 134 consecutive patients with an antemortem clinical diagnosis of MSA who came to autopsy with neuropathologic evaluation of the brain. Of the 134 patients, 125 had adequate medical records for review. Clinical and pathologic features were compared between patients with autopsy-confirmed MSA and those with other pathologic diagnoses, including dementia with Lewy bodies (DLB), Parkinson disease (PD), and progressive supranuclear palsy (PSP).

RESULTS:
Of the 134 patients with clinically diagnosed MSA, 83 (62%) had the correct diagnosis at autopsy. Pathologically confirmed DLB was the most common misdiagnosis, followed by PSP and PD. Despite meeting pathologic criteria for intermediate to high likelihood of DLB, several patients with DLB did not have dementia and none had significant Alzheimer-type pathology. Autonomic failure was the leading cause of misdiagnosis in DLB and PD, and cerebellar ataxia was the leading cause of misdiagnosis in PSP.

CONCLUSIONS:
The diagnostic accuracy for MSA was suboptimal in this autopsy study. Pathologically confirmed DLB, PD, and PSP were the most common diseases to masquerade as MSA. This has significant implications not only for patient care, but also for research studies in MSA cases that do not have pathologic confirmation.

© 2015 American Academy of Neurology.
PMID: 26138942

Methylene blue update

This post may only interest those of you following experimental drug therapies for PSP and CBD, both tauopathies (disorders of the protein tau).

In a review article from 2011, three tau-directed compounds were listed — methylene blue, tideglusib, and Davunetide.  Both the tideglusib and Davunetide trials in PSP were failures from a drug perspective.  (The great thing is that the worldwide PSP clinical treatment community and patient community showed that a worldwide PSP trial could be conducted.)

Now comes news that methylene blue stopped cognitive decline in tau-transgenic mice but only if the compound was given at the earliest stages.  This implies that if the compound were given in pre-symptomatic people with PSP or people in the early stages of CBD, that the compound might prevent them from getting worse.  Unfortunately we don’t now when someone is pre-symptomatic or in the early stages of PSP or CBD.

Some of you might remember there was an experimental drug called Rember, based on methylene blue.  The latest version of Rember is called LMT-X.  There are clinical trials going on now of LMT-X in Alzheimer’s and frontotemporal dementia.  LMT-X is made by TauRx Therapeutics.  One of the researchers there is Claude Wischik.  On the website Alzforum, Dr. Wischik argues that the data for LMT-X in humans is more positive.  And he’s still hopeful.

If you want all the nitty gritty details, check out this article on the Alzforum:

www.alzforum.org/news/research-news/et-tu-methylene-blue-drug-only-works-prophylactic

Robin